# Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS)

> **NCT01815632** · PHASE2 · UNKNOWN · sponsor: **North Bristol NHS Trust** · enrollment: 80 (estimated)

## Conditions studied

- Progressive Multiple Sclerosis

## Interventions

- **OTHER:** Early infusion of autologous marrow
- **OTHER:** Late infusion of autologous marrow

## Key facts

- **NCT ID:** NCT01815632
- **Lead sponsor:** North Bristol NHS Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-01
- **Primary completion:** 2019-10
- **Final completion:** 2019-10
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2018-06-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01815632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01815632, "Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01815632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*